| Title |
A multicenter phase II study of TSU-68, a novel oral multiple tyrosine kinase inhibitor, in patients with metastatic breast cancer progressing despite prior treatment with an anthracycline-containing regimen and taxane
|
|---|---|
| Published in |
International Journal of Clinical Oncology, May 2012
|
| DOI | 10.1007/s10147-012-0421-9 |
| Pubmed ID | |
| Authors |
Yasuhiro Suzuki, Toshiaki Saeki, Kenjiro Aogi, Masakazu Toi, Hirofumi Fujii, Kenichi Inoue, Toru Watanabe, Yasuhiro Fujiwara, Yoshinori Ito, Yuichi Takatsuka, Hiroji Iwata, Hitoshi Arioka, Yutaka Tokuda |
| Abstract |
TSU-68 is a novel multiple tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptor-2, platelet-derived growth factor receptor and fibroblast growth factor receptor. TSU-68 demonstrated a strong anti-tumor effect against established human breast cancer xenografts in nude mice without apparent toxicity. We conducted a phase II study to evaluate the efficacy and safety of TSU-68 monotherapy in patients with metastatic breast cancer progressing despite prior treatment with an anthracycline-containing regimen and taxane. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 28 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1 | 4% |
| Unknown | 27 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 8 | 29% |
| Student > Master | 4 | 14% |
| Lecturer | 3 | 11% |
| Student > Bachelor | 2 | 7% |
| Other | 2 | 7% |
| Other | 4 | 14% |
| Unknown | 5 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 14 | 50% |
| Biochemistry, Genetics and Molecular Biology | 2 | 7% |
| Psychology | 2 | 7% |
| Mathematics | 1 | 4% |
| Agricultural and Biological Sciences | 1 | 4% |
| Other | 2 | 7% |
| Unknown | 6 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 May 2012.
All research outputs
#20,157,329
of 22,665,794 outputs
Outputs from International Journal of Clinical Oncology
#615
of 905 outputs
Outputs of similar age
#148,325
of 163,696 outputs
Outputs of similar age from International Journal of Clinical Oncology
#6
of 6 outputs
Altmetric has tracked 22,665,794 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 905 research outputs from this source. They receive a mean Attention Score of 3.7. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 163,696 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 6 others from the same source and published within six weeks on either side of this one.